Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Subscribe To Our Newsletter & Stay Updated
